Current Lynch Syndrome Tumor Screening Practices: a Survey of Genetic Counselors

Overview

Journal J Genet Couns

Publisher Wiley

Specialty Genetics

Date 2013 May 16

PMID 23674164

Citations 27

Authors

Stephanie A Cohen

Affiliations

Soon will be listed here.

Abstract

An electronic survey of the National Society of Genetic Counselors Cancer Special Interest Group was conducted in July 2011 to assess Lynch syndrome tumor screening programs and identify barriers to implementation. Over half of respondents (52.8 %) reported having a routine Lynch syndrome tumor screening protocol for newly diagnosed colon and/or endometrial cancers, and approximately half of these used a universal approach. There was an increase in the number of those screening over time, especially in the past 3 years. Tumor screening methods varied; 34/53 (64.2 %) started with immunohistochemistry, 11/53 (20.8 %) started with microsatellite instability testing and 8/53 (15.1 %) performed both on newly diagnosed colorectal tumors. Just 21.7 % (23/106) of respondents indicated they have a tumor screening program in place for newly diagnosed endometrial cancers. Written consent is rarely obtained (7.1 %) and the method of how results were returned to the patient was variable among respondents. Prevalent barriers to implementation were concern about cost, bringing key players together and convincing medical staff of the necessity. Use of Lynch syndrome tumor screening is in clinical practice, but protocols vary widely. This survey provides a glimpse of current practices and common barriers, and identifies the need for tumor screening algorithms with outcomes data.

Citing Articles

A simplified two-marker immunohistochemistry strategy for Lynch syndrome screening in endometrial cancer patients.

Aiob A, Kim Y, Kim K, Kim H, Kim Y, Kim D Obstet Gynecol Sci. 2023; 66(6):537-544.

PMID: 37839795 PMC: 10663397. DOI: 10.5468/ogs.23124.

From Genetics to Histomolecular Characterization: An Insight into Colorectal Carcinogenesis in Lynch Syndrome.

Lepore Signorile M, Disciglio V, Di Carlo G, Pisani A, Simone C, Ingravallo G Int J Mol Sci. 2021; 22(13).

PMID: 34201893 PMC: 8268977. DOI: 10.3390/ijms22136767.

Stakeholders' views of integrating universal tumour screening and genetic testing for colorectal and endometrial cancer into routine oncology.

OShea R, Rankin N, Kentwell M, Gleeson M, Tucker K, Hampel H Eur J Hum Genet. 2021; 29(11):1634-1644.

PMID: 33811254 PMC: 8560784. DOI: 10.1038/s41431-021-00871-4.

Mismatch Repair Universal Screening of Endometrial Cancers (MUSE) in a Canadian Cohort.

Lawrence J, Richer L, Arseneau J, Zeng X, Chong G, Weber E Curr Oncol. 2021; 28(1):509-522.

PMID: 33467402 PMC: 7903281. DOI: 10.3390/curroncol28010052.

Effective Identification of Lynch Syndrome in Gastroenterology Practice.

Muller C, Matthews L, Kupfer S, Weiss J Curr Treat Options Gastroenterol. 2019; 17(4):666-680.

PMID: 31677041 PMC: 6986345. DOI: 10.1007/s11938-019-00261-2.

References

Hall M . Counterpoint: implementing population genetic screening for Lynch Syndrome among newly diagnosed colorectal cancer patients--will the ends justify the means?. J Natl Compr Canc Netw. 2010; 8(5):606-11. DOI: 10.6004/jnccn.2010.0045. View

Herman J, Umar A, Polyak K, Graff J, Ahuja N, Issa J . Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998; 95(12):6870-5. PMC: 22665. DOI: 10.1073/pnas.95.12.6870. View

Resnick K, Hampel H, Fishel R, Cohn D . Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol. 2009; 114(1):128-34. PMC: 2841434. DOI: 10.1016/j.ygyno.2009.03.003. View

Burks R, Kessis T, Cho K, Hedrick L . Microsatellite instability in endometrial carcinoma. Oncogene. 1994; 9(4):1163-6. View

Backes F, Mitchell E, Hampel H, Cohn D . Endometrial cancer patients and compliance with genetic counseling: room for improvement. Gynecol Oncol. 2011; 123(3):532-6. DOI: 10.1016/j.ygyno.2011.09.002. View

Pappa K, Choleza M, Markaki S, Giannikaki E, Kyroudi A, Vlachos G . Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol Oncol. 2005; 100(3):596-600. DOI: 10.1016/j.ygyno.2005.09.029. View

Dove-Edwin I, Sasieni P, Adams J, Thomas H . Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ. 2005; 331(7524):1047. PMC: 1283179. DOI: 10.1136/bmj.38606.794560.EB. View

Evans D, Walsh S, Hill J, McMahon R . Strategies for identifying hereditary nonpolyposis colon cancer. Semin Oncol. 2007; 34(5):411-7. DOI: 10.1053/j.seminoncol.2007.07.001. View

Sjursen W, Haukanes B, Grindedal E, Aarset H, Stormorken A, Engebretsen L . Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. J Med Genet. 2010; 47(9):579-85. PMC: 2976029. DOI: 10.1136/jmg.2010.077677. View

10.

Fitzgibbons Jr R, Lynch H, Stanislav G, Watson P, Lanspa S, Marcus J . Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II). Ann Surg. 1987; 206(3):289-95. PMC: 1493182. DOI: 10.1097/00000658-198709000-00007. View

11.

Stoffel E, Mukherjee B, Raymond V, Tayob N, Kastrinos F, Sparr J . Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009; 137(5):1621-7. PMC: 2767441. DOI: 10.1053/j.gastro.2009.07.039. View

12.

Beamer L, Grant M, Espenschied C, Blazer K, Hampel H, Weitzel J . Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol. 2012; 30(10):1058-63. PMC: 3341150. DOI: 10.1200/JCO.2011.38.4719. View

13.

Lynch H . Hereditary nonpolyposis colorectal cancer (HNPCC). Cytogenet Cell Genet. 1999; 86(2):130-5. DOI: 10.1159/000015365. View

14.

Zhang L . Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn. 2008; 10(4):301-7. PMC: 2438197. DOI: 10.2353/jmoldx.2008.080062. View

15.

Baglietto L, Lindor N, Dowty J, White D, Wagner A, Gomez Garcia E . Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2009; 102(3):193-201. PMC: 2815724. DOI: 10.1093/jnci/djp473. View

16.

Kwon J, Scott J, Gilks C, Daniels M, Sun C, Lu K . Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol. 2011; 29(16):2247-52. PMC: 4874206. DOI: 10.1200/JCO.2010.32.9979. View

17.

Weissman S, Burt R, Church J, Erdman S, Hampel H, Holter S . Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. J Genet Couns. 2011; 21(4):484-93. DOI: 10.1007/s10897-011-9465-7. View

18.

Cunningham J, Christensen E, Tester D, Kim C, Roche P, Burgart L . Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998; 58(15):3455-60. View

19.

Lu K, Schorge J, Rodabaugh K, Daniels M, Sun C, Soliman P . Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007; 25(33):5158-64. DOI: 10.1200/JCO.2007.10.8597. View

20.

Bellizzi A, Frankel W . Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol. 2009; 16(6):405-17. DOI: 10.1097/PAP.0b013e3181bb6bdc. View